SCHEMBL16618524

SCHEMBL16618524

COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CC(CCC(=O)c4ccccc4)C3)c12

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.72
CYP2C9 P11712 2/20 0.72
CYP2D6 P10635 2/20 0.72
CYP1A2 P05177 1/20 0.72
CYP2C8 P10632 1/20 0.72
CYP2B6 P20813 1/20 0.72
CYP2C19 P33261 1/20 0.72
KCNH2 Q12809 1/20 0.72
BTK Q06187 1/20 0.32
MAPT P10636 2/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPK1 P28482 1/20 0.32
GABRA1 P14867 2/20 0.31
GABRG2 P18507 2/20 0.31
GABRB3 P28472 2/20 0.31
GABRA3 P34903 2/20 0.31
GABRA2 P47869 2/20 0.31
GABRB2 P47870 2/20 0.31
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25112951 0.89 CYP3A4 (0.57) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL25112509 0.89 CYP3A4 (0.56) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL16619080 0.87 CYP3A4 (0.71) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL14754237 0.86 CYP2C19 (0.84) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL17953056 0.86 CYP2C19 (0.84) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
Temsavir SCHEMBL760768 0.84 CYP2C19 (1.00) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL13464991 0.84 CYP2C19 (0.88) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL16618731 0.83 CYP3A4 (0.65) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
SCHEMBL14754194 0.83 CYP3A4 (0.68) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8
Temsavir SCHEMBL14867762 0.82 CYP2C19 (0.85) CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160214998-A1 NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME DREXEL UNIVERSITY (US) 2016-07-28 US claimed
WO-2015051230-A1 NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME DREXEL UNIVERSITY (US) 2015-04-09 WO claimed
US-9920073-B2 Compositions useful for inhibiting HIV-1 infection and methods using same DREXEL UNIVERSITY (US) 2018-03-20 US disclosed
US-9920073-B2 Compositions useful for inhibiting HIV-1 infection and methods using same DREXEL UNIVERSITY (US) 2018-03-20 US disclosed
US-9920073-B2 Compositions useful for inhibiting HIV-1 infection and methods using same DREXEL UNIVERSITY (US) 2018-03-20 US disclosed
US-20160214998-A1 NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME DREXEL UNIVERSITY (US) 2016-07-28 US disclosed
US-20160214998-A1 NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME DREXEL UNIVERSITY (US) 2016-07-28 US disclosed
US-20160214998-A1 NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME DREXEL UNIVERSITY (US) 2016-07-28 US disclosed
WO-2015051230-A1 NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME DREXEL UNIVERSITY (US) 2015-04-09 WO disclosed
WO-2015051230-A1 NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME DREXEL UNIVERSITY (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160214998-A1 NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME CCL5, CCR5, CXCL10 CYP3A4 4235/4885CYP2C9 4831/4885CYP2D6 4602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.